Bivalent ligands for G protein-coupled receptors

Current Pharmaceutical Design

Volumn 10, Issue 17, 2004, Pages 2015-2020

  Messer Jr , William S ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Bivalent ligand; Drug design; Muscarinic receptor; Opioid receptor; Serotonin receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 3 PIPERIDEINE DERIVATIVE; ACECLIDINE; ARECAIDINE PROPARGYL ESTER; ARECOLINE; BRUCINE; BUSPIRONE; CARBACHOL; CEVIMELINE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GALLAMINE; GUANIDINOACETIC ACID; GUANIDYLNATRINDOLE; INDOLE DERIVATIVE; LIGAND; MORPHINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; NALTREXONE; NORBINALTORPHIMINE; OPIATE AGONIST; OPIATE RECEPTOR; QUINUCLIDINE DERIVATIVE; RECEPTOR SUBTYPE; SEROTONIN RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANXIETY DISORDER; BINDING AFFINITY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; MIGRAINE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SCHIZOPHRENIA;

ANIMALS; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, MUSCARINIC; RECEPTORS, OPIOID; RECEPTORS, SEROTONIN;

EID: 3042684536     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384213     Document Type: Review

References (50)

1. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther 1988; 246: 255-8.
2. Portoghese PS, Nagase H, Takemori AE. Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine. J Med Chem 1988; 31: 1344-7.
3. Lalchandam SG, Lei L, Zheng W, Suni MM, Moore BM, Liggett SB, et al. Yohimbine dimers exhibiting selectivity for the human alpha 2C-adrenoceptor subtype. J Pharmacol Exp Ther 2002; 303: 979-84.
4. Abadi AH, Lankow S, Hoefgen B, Decker M, Kassack MU, Lehmann J. Dopamine/serotonin receptor ligands, part III [1]: synthesis and biological activities of 7, 7′-alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines - application of the bivalent ligand approach to a novel type of dopamine receptor antagonist. Arch Pharm (Weinheim) 2002; 335: 367-73.
5. Halazy S, Perez M, Fourrier C, Pallard I, Pauwels PJ, Palmier C, et al. Serotonin dimers: application of the bivalent ligand approach to the design of new potent and selective 5-HT(1B/1D) agonists. J Med Chem 1996; 39: 4920-7.
6. Perez M, Jorand-Lebrun C, Pauwels PJ, Pallard I, Halazy S. Dimers of 5HT1 ligands preferentially bind to 5HT1B/1D receptor subtypes. Bioorg Med Chem Lett 1998; 8: 1407-12.
7. Perez M, Pauwels PJ, Fourrier C, Chopin P, Valentin JP, John GW, et al. Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist. Bioorg Med Chem Lett 1998; 8: 675-80.
8. Christopoulos A, Grant MK, Ayoubzadeh N, Kim ON, Sauerberg P, Jeppesen L, et al. Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther 2001; 298: 1260-8.
9. Rajeswaran WG, Cao Y, Huang XP, Wroblewski ME, Colclough T, Lee S, et al. Design, Synthesis, and Biological Characterization of Bivalent 1-Methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole Derivatives as Selective Muscarinic Agonists. J Med Chem 2001; 44: 4563-4576.
10. Messer WS, Rajeswaran JR, Cao WG, Zhang Y, El-Assadi HJ, Dockery AA, et al. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Pharm Acta Helv 2000; 74: 135-40.
11. Portoghese PS. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. J Med Chem 2001; 44: 2259-69.
12. Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. Mutational evidence for a common kappa antagonist binding pocket in the wild-type kappa and mutant mu[K303E] opioid receptors. J Med Chem 1998; 41: 4911-4.
13. Rios CD, Jordan BA, Gomes I, Devi LA. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 2001; 92: 71-87.
14. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-5.
15. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996; 48: 567-92.
16. Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist nor-binaltorphimine. Mol Pharmacol 1995; 47: 1089-94.
17. Glennon RA, Hong SS, Dukat M, Teitler M, Davis K. 5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist. J Med Chem 1994; 37: 2828-30.
18. Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M, et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986; 323: 411-6.
19. Kubo T, Maeda A, Sugimoto K, Akiba I, Mikami A, Takahashi H, et al. Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett 1986; 209: 367-72.
20. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987; 237: 527-32.
21. Peralta EG, Ashkenazi A, Winslow JW, Smith DH, Ramachandran J, Capon DJ. Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J 1987; 6: 3923-9.
22. Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988; 1: 403-10.
23. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998; 50: 279-90.
24. Hersch SM, Gutekunst CA, Rees HD, Heilman CJ, Levey AI. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 1994; 14: 3351-63.
25. Levey AI, Edmunds SM, Koliatsos V, Wiley RG, Heilman CJ. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J Neurosci 1995; 15: 4077-92.
26. Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci USA 1996; 93: 13541-6.
27. Weiner DM, Levey AI, Brann MR. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 1990; 87: 7050-4.
28. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003; 6: 51-8.
29. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 2002; 22: 1709-17.
30. Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci 2001; 68: 2605-13.
31. Basile AS, Fedorova I, Zapata A, Liu X, Shippenberg T, Duttaroy A, et al. Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc Natl Acad Sci USA 2002; 99: 11452-7.
32. Abood LG, Biel JH. Anticholinergic psycholomimetic agents. Int Rev Neurobiol 1962; 4: 217-273.
33. Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998; 6: S64-78.
34. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 1999; 45 Suppl 1: 15-22.
35. Cummings JL. The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. Int J Neuropsychopharmacol 2000; 3: 21-29.
36. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 1999; 45: 1-16.
37. Fraser CM, Wang CD, Robinson DA, Gocayne JD, Venter JC. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol 1989; 36: 840-7.
38. Wess J, Gdula D, Brann MR. Site-directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. EMBO J 1991; 10: 3729-34.
39. Wess J, Maggio R, Palmer JR, Vogel Z. Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. J Biol Chem 1992; 267: 19313-9.
40. Huang XP, Nagy PI, Williams FE, Peseckis SM, Messer WS Jr. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors. Br J Pharmacol 1999; 126: 735-45.
41. Allman K, Page KM, Curtis CA, Hulme EC. Scanning Mutagenesis Identifies Amino Acid Side Chains in Transmembrane Domain 5 of the M(1) Muscarinic Receptor that Participate in Binding the Acetyl Methyl Group of Acetylcholine. Mol Pharmacol 2000; 58: 175-184.
42. Allman K, Page KM, Curtis CA, Hulme EC. Scanning mutagenesis identifies amino acid side chains in transmembrane domain 5 of the M(1) muscarinic receptor that participate in binding the acetyl methyl group of acetylcholine. Mol Pharmacol 2000; 58: 175-84.
43. Bluml K, Mutschler E, Wess J. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem 1994; 269: 18870-6.
44. Bluml K, Mutschler E, Wess J. Identification of an intracellular tyrosine residue critical for muscarinic receptor-mediated stimulation of phosphatidylinositol hydrolysis. J Biol Chem 1994; 269: 402-5.
45. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, et al. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 2002; 61: 1297-302.
46. Moser U, Gubitz C, Galvan M, Immel-Sehr A, Lambrecht G, Mutshcler E. Aliphatic and heterocyclic analogues of arecaidine propargyl ester. Structure-activity relationships of mono- and bivalent ligands at muscarinic M1 (M4), M2 and M3 receptor subtypes. Arzneimittelforschung 1995; 45: 449-55.
47. Cao Y, Zhang M, Wu C, Lee S, Wroblewski ME, Whipple T, et al. Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders. J Med Chem 2003; 46: 4273-4286.
48. Horvath TL, Castaneda T, Tang-Christensen M, Pagotto U, Tschop MH. Ghrelin as a potential anti-obesity target. Curr Pharm Design 2003; 9(17): 1383-95.
49. Schechter LE, Dawson LA, Harder JA. The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease. Curr Pharm Design 2002; 8(2): 139-45.
50. Teschemacher H. Opioid receptor ligands derived from food proteins. Curr Pharm Design 2003; 9(16): 1331-44.